Breceptin

Drug Profile

Breceptin

Alternative Names: B201; B201-acetate

Latest Information Update: 29 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ApopLogic Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Bradykinin B1 receptor antagonists; Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Non-small cell lung cancer; Prostate cancer

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 29 Aug 2016 Preclinical development is underway for Solid tumours in USA.
  • 25 Aug 2016 Breceptin is available for licensing as of 25 Aug 2016. http://www.apoplogic.com/
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top